Clock

Clock

Molina's dislocation was a 2025 Medicaid cost-trend miss, and the repair mechanism is mechanical: the state rate cycle catching up to a cost base management puts 20% above where it stood three years ago [1]. Management sizes that catch-up at roughly $7.25 of EPS toward a 2029 target of $25 [2]. The distinctive fact for this clock: the market has already re-rated the stock +83% off its February 2026 trough, and it now trades above the average analyst target.

What would close the gap

The dislocation this tab is timing is a healthcare forecasting error, not a broken franchise — the pattern of an insurer that mis-forecast one year's cost trend and was marked down as if the miss were permanent. What closes the gap is the repricing machinery of Medicaid itself, and three of its parts are already turning.

The rate cycle catches up to the cost base — on a dated, recurring calendar. Molina's 2025 medical cost trend ran 7.5%, of which 250 basis points was an acuity shift as low- and no-utilizers left the rolls after the post-pandemic redetermination [3]. Medicaid premiums are reset by each state on an actuarial cycle — a January 1 update for most states, plus off-cycle and retro adjustments through the year — so the fix is structural, not discretionary. Management's 2026 Medicaid MCR guide of 92.9% is built on rate increases of 4% against a 5% trend, with the note that "states continue to update their actuarial data to reflect higher observed trends" [4]. On the first-quarter call the CEO framed the mechanism plainly: states "are catching up" to a cost baseline "20% higher than it was three years ago," and because Molina runs "300 to 400 basis points better than the average market," margin should move "into much more positive territory" as they do [5]. The evidence it is in motion: the January 1, 2026 rate updates "came in as expected," first-quarter trend ran modestly favorable, and several states had already granted off-cycle rate increases that management flagged as upside to guidance [6].

Guidance resets against a deliberately low bar, and the reset quarter is now. Full-year 2026 is guided to "at least $5" of adjusted EPS on roughly $42 billion of premium [7] — a floor set after a year of downward revisions, against which a beat re-rates more than a raise from a stretched bar would. Management told the market it would reset the full-year number with second-quarter results: "when we report second quarter results, we will update our full year 2026 guidance … a time-tested base off of which to project the second half" [8]. That print lands July 22, 2026.

A mechanical earnings tailwind turns positive in 2027. Molina carries roughly $2.50 per share of "embedded earnings" — the drag from 2026 MAPD Medicare losses and Florida CMS first-year implementation costs — both of which management calls "certain to be positive impacts to our 2027 performance," with the MAPD product being exited for 2027 [9]. This is independent of the rate cycle: two known cost items roll off on a fixed schedule.

Management put the full bridge on a slide at its May 8, 2026 Investor Day. From the 2026 base of at least $5, it targets $25 of adjusted EPS by 2029 — $7.25 from "current revenue MCR recovery" (the rate catch-up), $6.00 from operating discipline, and $6.75 from revenue growth — and states the case that "current margin compression is cyclical and temporary" [10] [11]. The single largest component of that bridge is the rate repricing this tab is timing [12]. Buybacks add a fourth, smaller lever — the Self-Help tab covers the $1 billion-a-year pace that took the share count from 57.7 million (FY2024) to 52.9 million (FY2025).

The dated catalyst path

Sources: guidance-reset and rate-cycle commitments from the Q1 FY2026 earnings call [13] [14]; Q2 date from the consensus earnings calendar (as reported); Q3/Q4 windows from the company's historical late-October and early-February cadence.

Base rates from Molina's own history

Over a listed history back to 2003, Molina has fallen 30% or more from a prior high six times. The current decline is the deepest of them. The deterministic capitulation gauge dates the peak to the September 16, 2024 close of $360.77 and the trough to $122.65 on February 11, 2026 — a 66.0% fall over about 17 months; measured from the March 2024 all-time high of $419.53 the drop was 70.8%. Either way it is the deepest peak-to-trough decline in the name's history, and the volume capitulation the Dislocation tab documents places peak fear in early 2026, not at the start of the slide.

Source: derived from the run's daily price history, 2003–2026 (as reported). Depth = (trough close − peak close) / peak close; current-episode depth per the deterministic capitulation gauge (peak 2024-09-16, trough 2026-02-11).

Source: derived from the run's daily price history, 2003–2026 (as reported). Round-trip = trading days from prior peak to first close back at that peak; the current episode has not round-tripped.

Two patterns matter. In its mature large-cap era, Molina's one comparable-depth drawdown — the 2015–2018 ACA/Medicaid margin scare, down 47.6% — took roughly 29 months to round-trip; the shallower ~31% sector de-rates repaired in 8 to 10 months. The current fall is deeper than any of those, which on the name's own base rate argues a full round-trip to the prior high is a two-year-plus process, not an 18-month one. Against that, the partial recovery already in hand has been faster than the base rate: from the $122.65 trough the stock reached $224.82 by July 16, 2026, a +83% move in about five months, leaving it 37.7% below the September 2024 peak and 46.4% below the all-time high.

The 18-month test

Partial re-recognition within 18–24 months is a reasonable expectation, and much of the first leg has already printed; a full round-trip to the prior $360–$420 highs is not supported inside that window by the name's own history. The evidence for the near-term half: the January 2026 rate updates landed as expected, off-cycle increases are already arriving, the acuity shift is described as largely behind the book, and consensus has FY2027 adjusted EPS at $9.29 and FY2028 at $12.93 against an FY2026 trough of $5.16 — recovery that shows up in printed numbers over exactly this window. The evidence against a full round-trip on the same clock: management's own bridge routes the return to $25 of EPS through 2029, and the comparable 2015–2018 drawdown took ~29 months to fully repair. The read tied to the falsifier ledger: this clock runs on the Medicaid rate cycle funding a cost base 20% higher than three years ago. It is falsified if the 2027 rate updates fail to close that gap, if medical cost trend re-accelerates above the 5% assumption, or if the acuity shift proves not to be behind the book — any of which would turn a cyclical repricing into a structural margin reset, the distinction the Damage Math tab adjudicates.

What consensus expects, and when

The sell side is neither capitulated short nor crowded long. Of 19 covering analysts, 3 rate Molina a buy, 15 a hold, and 1 an underperform — a consensus that sat out both the fall and the bounce. More telling for a re-rating: after the +83% recovery, the stock at $224.82 trades above the mean price target of $210.76 and the median of $209 (targets range $129 to $286). The market has already priced in more recovery than the average analyst, which leaves the near-term re-rating dependent on the printed numbers rather than on the street catching up.

Source: analyst price targets and recommendations, CapIQ/consensus feed as of 2026-07-17 (n=17 targets, 19 ratings); current price from the run's daily price history.

The candidate quarter for re-recognition is the one reporting July 22, 2026: management pre-committed to resetting the full-year guide with second-quarter results, and it is doing so from a "at least $5" floor after a Q1 that beat and after off-cycle rate increases it had not yet banked. Beyond that, consensus itself locates the recovery in the FY2027 numbers — where the embedded-earnings drag reverses and the rate catch-up compounds — with the first full FY2027 outlook due at the early-February 2027 print. The forward-FCF-yield path underlying those estimates is the Yield tab's to adjudicate; it is lumpy on Medicaid receivable timing, computing to 15.6% on FY2026 consensus FCF and 9.6% on FY2028 against the current $11.9 billion market capitalization.

The instruments

Long-dated listed options on Molina exist. Standard monthly series are supplemented by LEAPS expiring January 15, 2027 and January 21, 2028 — the latter roughly 18 months out as of July 2026 — so an expression that spans the framework's 18-month-plus horizon is available on-screen. Liquidity is the deep single-name liquidity typical of an S&P 500 constituent; specific open-interest figures at each long-dated strike were not verifiable from the sources reviewed and are not estimated here.

Current 30-day implied volatility reads 63.86% (AlphaQuery, dated 2026-07-21). That sits in the elevated 60–70 band rather than the up-to-~50–55 range, and it is inflated by the July 22, 2026 earnings print that the options market is positioned around; it is a spot reading on an event date, not a settled level. Verdict: qualifying long-dated options exist. This section states instrument facts only — no strike, expiry, structure, or sizing is implied.

Sources: options-listing calendar and expirations from public options-chain data (Barchart, Investing.com), July 2026, as reported; 30-day implied volatility from AlphaQuery (MOH), 2026-07-21. No filing page backs these market-data facts; they are cited to their dated web sources rather than a PDF.